Excerpt from Los Angeles Times
-- "'If brand-name manufacturers do not get their investment worth, guess what — no new drugs,' said Rosa Abrantes-Metz
, an adjunct associate professor at New York University's Leonard N. Stern School of Business. 'And then who loses? All of us.'"